Personalized Peripheral Nerve Stimulation for Inflammatory Bowel Disease Treatment

A next-generation system for treating inflammatory bowel disease through adaptive, personalized peripheral nerve stimulation, leveraging machine learning, real-time neural monitoring, and precision targeting of specific nerve fibers involved in inflammatory pathways.

The original patent disclosed a method for treating inflammatory bowel disease through peripheral nerve stimulation, but it had limitations in terms of personalization, adaptability, and precision targeting. The new inventive concept addresses these limitations by introducing machine learning-based optimization, real-time neural monitoring, and precision targeting of specific nerve fibers, enabling more effective and personalized treatment outcomes.

The new inventive concept comprises a neural interface module for real-time monitoring of neural activity, a machine learning module for predicting optimal stimulation parameters based on patient-specific data, and a stimulation module for delivering personalized, adaptive electrical stimulation signals to a peripheral nerve. The system can be implemented as a wearable device, featuring a flexible, implantable neural interface, a miniaturized stimulation module, and a power source sustaining device operation for at least 30 days. Additionally, the system can incorporate high-resolution, 3D neural mapping to identify specific nerve fibers involved in inflammatory pathways, and a feedback module for adjusting stimulation parameters based on real-time patient feedback.

The new claims introduce the novel concept of personalized, adaptive peripheral nerve stimulation, which is not present in the original patent. The use of machine learning, real-time neural monitoring, and precision targeting of specific nerve fibers represents a significant departure from the original patent's methods, providing a more effective and personalized treatment approach.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, varying stimulation parameters, or incorporating additional sensors for monitoring patient biomarkers. Variations could also involve different wearable device designs, implantable neural interfaces, or power sources.

The new inventive concept has significant commercial potential in the treatment of inflammatory bowel disease, with a target market of pharmaceutical companies, medical device manufacturers, and healthcare providers. The system's ability to provide personalized, adaptive treatment could lead to improved treatment outcomes, reduced healthcare costs, and enhanced patient quality of life.